Search Result for Drug name

Aminocaproic Acid

CARDIOVASCULAR SYSTEM

COAGULANTS - [ CARDIOVASCULAR SYSTEM ]

Aminocaproic acid is an antifibrinolytic drug which competes which competes for lysine binding sites of plasminogen and plasmin thus inhibiting their interaction with fibrin(1)

Enhancement of haemostasis when fibrinolysis contributes to bleeding (2)

Evidence of an active intravascular clotting process When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC) Presence of DIC without concomitant heparin. (2)

General: Edema, headache, malaise. Hypersensitivity Reactions: Allergic and anaphylactoid reactions, anaphylaxis. Cardiovascular: Bradycardia, hypotension, peripheral ischemia, thrombosis. Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting. Hematologic: Agranulocytosis, coagulation disorder, leukopenia, thrombocytopenia Musculoskeletal: CPK increased, muscle weakness, myalgia, myopathy rhabdomyolysis. Neurologic: Confusion, convulsions, delirium, dizziness, hallucinations, intracranial hypertension, stroke, syncope. Respiratory: Dyspnea, nasal congestion, pulmonary embolism. Skin: Pruritis, rash. Special Senses: Tinnitus, vision decreased, watery eyes. Urogenital: BUN increased, renal failure (2)

Oral contraceptives: Increased risk of bleeding (2)

It should be used be exercised with caution in pregnant women and nursing mothers Safety and effectiveness in pediatric patients have not been established Caution in patients of renal impairment (2)

For the treatment of acute bleeding syndromes due to elevated fibrinolytic activity, it is suggested that 5 X 1000 mg Tablets or 10 X 500 mg Tablets (5 g) or 4 teaspoonfuls of Oral Solution (5 g) be administered during the first hour of treatment, followed by a continuing rate of one 1000 mg Tablet or two 500 mg Tablets (1 g) or 1 teaspoonful of Oral Solution (1.25 g) per hour. This method of treatment would ordinarily be continued for about 8 hours or until the bleeding situation has been controlled. (2)

1.Weitz JZ. Blood coagulation and anticoagulants, fibrinolytics and antiplatelet drugs. In: Brunton L, Chabner B, Knollmann B eds. Goodman & Gilman’s The Pharmacological basis of Therapeutics. 12th ed. China: McGraw Hill; 2011. P849-77 2. Amicar [Internet]. [cited 2013 September 13]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/015197s043,015230s035lbl.pdf